Irina V. Vasilevskaya – PhD, MD, oncologist, radiotherapist, Researcher, Department of Fundamental Research, Group of Molecular Biological Prediction and Individualization of Treatment, RRCRT named after A.I. A. M. Granova, St. Petersburg, Russia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Oleg E. Molchanov – PhD, MD, oncologist, Head of the Department of Fundamental Research, Group of Molecular Biological Prediction and Individualization of Treatment, RRCRT named after A.I. A. M. Granova, St. Petersburg, Russia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it..
1. World Health Organization “Releases Latest Global Cancer Data” September 13, 2018. By World Health Organization
2. Kaprina AD, Starinskii VV, Petrovoi GV, editors. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2017 godu. M.: MNIOI im. P.A. Gertsena, filial FGBU “NMITs radiologii” Minzdrava Rossii; 2018. (In Russ).
3. Halsted WS. I. The Results of Radical Operations for the Cure of Carcinoma of the Breast. Ann Surg. 1907;46(1):1-19. DOI:10.1097/00000658-190707000-00001
4. Fisher B. Laboratory and clinical research in breast cancer – a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res. 1980;40(11):3863-74.
5. Hellman S, Harris JR. The appropriate breast cancer paradigm. Cancer Res. 1987;47(2):339-42.
6. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797): 747-52. DOI:10.1038/35021093
7. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-7. DOI: 10.1200/ JCO.2008.18.1370
8. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet. 2001;357(9255):539-45. DOI: 10.1016/S0140-6736(00)04046-0
9. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991-8. DOI: 10.1038/ni1102-991
10. Law AM, Lim E, Ormandy CJ, Gallego-Ortega D. The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy [published correction appears in Endocr Relat Cancer. 2017 Jul;24(7): X1]. Endocr Relat Cancer. 2017;24(4):R123-44. DOI: 10.1530/ ERC-16-0404
11. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137-46. DOI: 10.1172/JCI31405
12. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-99. DOI: 10.1016/j.cell.2010.01.025
13. Varn FS, Mullins DW, Arias-Pulido H, et al. Adaptive immunity programmes in breast cancer. Immuno-logy. 2017;150(1):25-34. DOI:10.1111/imm.12664
14. Molchanov OE. Immunoterapiya pochechno-kletochnogo raka. Sovremennoe sostoyanie problemy i perspektivnye napravleniya issledovanii. Urologicheskie vedomosti. 2018;8(3):67-79. (In Russ).
15. Khaitov RM, Kadagidze ZG. Immunitet i rak. Moscow: GEOTAR; 2018. (In Russ).
16. Sugie T, Toi M. Antitumor immunity and advances in cancer immunotherapy. Breast Cancer. 2017;24(1):1-2. DOI: 10.1007/s12282-016-0744-x
17. De la Cruz-Merino L, Chiesa M, Caballero R, et al. Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives. Int Rev Cell Mol Biol. 2017;331:1-53. DOI: 10.1016/bs.ircmb.2016.09.008
18. Zhang H, Chen J. Current status and future direc-tions of cancer immunotherapy. J Cancer. 2018;9(10):1773-81. Published 2018 Apr 19. doi:10.7150/jca.24577
19. Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335-7. DOI: 10.1172/JCI83871
20. Wojtowicz ME, Dunn BK, Umar A. Immunologic approaches to cancer prevention-current status, challenges, and future perspectives. Semin Oncol. 2016;43(1):161-72. DOI: 10.1053/j.seminoncol.2015.11.001
21. Criscitiello C, Curigliano G. Immunotherapeutics for breast cancer. Curr Opin Oncol. 2013;25(6):602-8. DOI: 10.1097/CCO.0000000000000020
22. Ayoub NM, Al-Shami KM, Yaghan RJ. Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. Breast Cancer (Dove Med Press). 2019;11:53-69. Published 2019 Jan 17. DOI: 10.2147/BCTT.S175360
23. Oakes SR, Gallego-Ortega D, Ormandy CJ. The mammary cellular hierarchy and breast cancer. Cell Mol Life Sci. 2014;71(22):4301-24. DOI: 10.1007/s00018-014-1674-4
24. Macias H, Hinck L. Mammary gland development. Wiley Interdiscip Rev. Dev Biol. 2012;1(4):533-57. DOI: 10.1002/wdev.35
25. McCready J, Arendt LM, Rudnick JA, Kuperwasser C. The contribution of dynamic stromal re-modeling during mammary development to breast carcino-genesis. Breast Cancer Res. 2010;12(3):205. DOI: 10.1186/bcr2578
26. Watson CJ, Kreuzaler PA. Remodeling mechanisms of the mammary gland during involution. Int J Dev Biol. 2011;55(7-9):757-62. DOI: 10.1387/ijdb.113414cw
27. Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228-41. DOI: 10.1038/nrclinonc.2015.215
28. Emens LA. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther. 2012;12(12):1597-611. DOI: 10.1586/era.12.147
29. Stanton SE, Adams S, Disis ML. Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncol. 2016;2(10):1354-60. DOI: 10.1001/jamaoncol.2016.1061
30. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158-65. DOI: 10.1158/1078-0432.CCR-07-4756
31. Cohen IJ, Blasberg R. Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast. Cancer Breast Cancer (Auckl). 2017;11: 1178223417731565. Published 2017 Sep 25. DOI: 10.1177/1178223417731565
32. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumorinfiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860-7. DOI: 10.1200/JCO.2011.41.0902
33. Cimino-Mathews A, Foote JB, Emens LA. Immune targeting in breast cancer. Oncology (Williston Park). 2015;29(5):375-85.
34. West NR, Milne K, Truong PT, et al. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13(6):R126. DOI: 10.1186/ bcr3072
35. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014;27:1-7. DOI: 10.1016/j.coi.2013.12.005
36. Su S, Liao J, Liu J, et al. Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer. Cell Res. 2017;27(4):461-82. DOI: 10.1038/cr.2017.34
37. Sharma MD, Baban B, Chandler P, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest. 2007;9(117):2570-82. DOI: 10.1172/JCI31911
38. Shou D, Wen L, Song Z, et al. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the micro-environment of breast cancer and targeted immunotherapies. Oncotarget. 2016;7(39):64505-11. DOI: 10.18632/oncotarget.11352
39. Duechler M, Peczek L, Zuk K, et al. The hetero-geneous immune microenvironment in breast cancer is affected by hypoxia-related genes. Immunobiology. 2014;219(2):158-65. DOI: 10.1016/j.imbio.2013.09.003
40. Bergenfelz C, Larsson AM, von Stedingk K, et al. Systemic Monocytic-MDSCs Are Generated from Mono-cytes and Correlate with Disease Progression in Breast Cancer Patients. PLoS One. 2015;10(5):e0127028. Published 2015 May 20. DOI: 10.1371/journal.pone.0127028
41. Montero AJ, Diaz-Montero CM, Deutsch YE, et al. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophos-phamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res Treat. 2012;132(1):215-23. DOI: 10.1007/s10549-011-1889-0
42. Sawant A, Deshane J, Jules J, et al. Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res. 2013;73(2):672-82. DOI: 10.1158/0008-5472.CAN-12-2202
43. Sawant A, Ponnazhagan S. Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease. Oncoimmunology. 2013;2(5):e24064. DOI: 10.4161/onci.24064
